Insights on the Liquid Biopsy Global Market to 2028 – Featuring Biocept, Epigenomics, Exosome Diagnostics and Lariat Biosciences Among Others – ResearchAndMarkets.com

Insights on the Liquid Biopsy Global Market to 2028 – Featuring Biocept, Epigenomics, Exosome Diagnostics and Lariat Biosciences Among Others – ResearchAndMarkets.com




Insights on the Liquid Biopsy Global Market to 2028 – Featuring Biocept, Epigenomics, Exosome Diagnostics and Lariat Biosciences Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Liquid Biopsy Market Research and Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering.

The global liquid biopsy market is anticipated to grow at a significant CAGR of 17.3% during the forecast period. One of the core factors that is fueling the market is the rising prevalence of cancer diseases.

Companies Mentioned

  • Biocept Inc.
  • Biodesix, Inc.
  • Circulogene
  • Clearbridge Biomedics Pte Ltd.
  • Cynvenio Biosystems, Inc.
  • Epigenomics AG
  • Exosome Diagnostics Inc.
  • F. Hoffmann-La Roche AG
  • Genomic Health Inc.
  • Inivata Ltd.
  • Lariat Biosciences, Inc.
  • Menarini-Silicon Biosystems
  • Personal Genome Diagnostics Inc.
  • Raindance Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • Trovagene, Inc.

There are several kinds of cancers such as lung cancer, breast cancer, prostate cancer, colorectal cancer, and other cancers which have been examined over the decade, and cases are growing every year. Along with various methods, this has pushed the demand for liquid biopsy to find the tumor cells in the blood.

The treatment has been helping to find the tumor precisely in real-time which helped to recognize the symptoms of cancer at the initial stage to treat cancer successfully. As per the World Health Organization (WHO) report in 2020, cancer was the leading cause of death worldwide, with an estimated 10 million fatalities.

Segmental Outlook

The global liquid biopsy market is segmented based on the biomarker type, cancer type, and end-user. Based on the biomarker type, the market is segmented into circulating tumor cells, circulating tumor DNA, and others. The other biomarker type includes extracellular vesicles. Based on the cancer type, the market is segmented into lung cancer, breast cancer, prostate cancer, colorectal cancer, and other cancers.

Based on the end-user, the market is sub-segmented into the hospitals and laboratories, and academic and research centers. The above-mentioned segments can be customized as per the requirements. Based on cancer type, breast cancer is estimated to hold a prominent share in the market while based on end-user, the hospitals and laboratories segment is anticipated to hold a prominent share during the forecast period.

The Breast Cancer Segment Estimated to Hold the Prominent Share in the Global Liquid Biopsy Market

Based on cancer, the breast cancer segment is anticipated to hold a prominent share in the market during the forecast period. Breast cancer is considered the most common cancer in women and has become the fifth leading cause of mortality in the past few years.

As per the report of WHO, in 2020, there were 2.3 million women diagnosed with breast cancer, and 685 000 fatalities registered globally. By the end of 2020, 7.8 million women were living who was diagnosed with breast cancer in the last past 5 years, making it the world’s most prevalent cancer. Early detection and treatment can reduce the mortality rate. A biopsy is a process that can find if the suspicious area is cancerous. A breast biopsy test can remove sometimes fluid or tissue from the suspicious part, and the removed cells are inspected under a microscope and further tested, to check for the presence of breast cancer.

Regional Outlooks

The global liquid biopsy market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North America is projected to dominate the market while the Asia-Pacific is projected to witness the highest growth rate during the forecasted period.

North America Region Anticipated to Dominate the Market in the Global Liquid Biopsy Market

North American region is estimated to dominate the market during the forecast period owing to the fact that cancer is the 2nd most common cause of death in the US which has increased the demand for cancer diagnosis and treatment in the country including liquid biopsy. As per the American Cancer Society, Inc. in 2021, 1.9 million new cancer cases are estimated to be diagnosed and 608,570 cancer deaths in the US, which is projected to drive the market during the forecast period.

Furthermore, as per John Hopkins Medicine, the elderly population is at high risk of getting affected with cancer, and the geriatric population is expected to increase from 53.340 million in 2019 to 83.813 million in 2050, as per the World Ageing Report 2019. Thus, the growing geriatric population is expected to result in a high incidence of cancer, which will raise the demand for liquid biopsies for countering the issue.

The Report Covers

  • Market value data analysis of 2021 and forecast to 2028.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global liquid biopsy market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.

For more information about this report visit https://www.researchandmarkets.com/r/d4sx8a

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900